[go: up one dir, main page]

AR037330A1 - Derivado de quinazolina, composicion farmaceutica, su uso en la fabricacion de un medicamento y proceso para preparar dicho derivado de quinazolina - Google Patents

Derivado de quinazolina, composicion farmaceutica, su uso en la fabricacion de un medicamento y proceso para preparar dicho derivado de quinazolina

Info

Publication number
AR037330A1
AR037330A1 ARP020104181A ARP020104181A AR037330A1 AR 037330 A1 AR037330 A1 AR 037330A1 AR P020104181 A ARP020104181 A AR P020104181A AR P020104181 A ARP020104181 A AR P020104181A AR 037330 A1 AR037330 A1 AR 037330A1
Authority
AR
Argentina
Prior art keywords
alkyl
amino
group
carbamoyl
heterocyclyl
Prior art date
Application number
ARP020104181A
Other languages
English (en)
Inventor
Laurent Hennequin
Jason Kettle
Martin Pass
Robert Bradbury
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0126433.2A external-priority patent/GB0126433D0/en
Priority claimed from GB0129059A external-priority patent/GB0129059D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR037330A1 publication Critical patent/AR037330A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Un derivado de quinazolina que responde a la fórmula (1), donde: R1 es hidrógeno o alquilo (C1-6); Z es un enlace directo o se selecciona entre O, S y N(R2), donde R2 es hidrógeno o alquilo (C1-6); Q1 es cicloalquilo (C3-7), cicloalquil (C3-7)-alquilo (C1-6), cicloalquelino (C3-7), cicloalquenil (C3-7)-alquilo (C1-6), heterociclilo o heterociclil-alquilo (C1-6), y donde los átomos de carbono adyacentes en cualquier cadena alquileno (C2-6) dentro del grupo Q1-Z- se separan opcionalmente por la inserción en la cadena de un grupo seleccionado entre O, S, SO, SO2, N(R3), CO, CH(OR3), CON(R3), N(R3)CO, SO2N(R3), N(R3)SO2, CH=CH y CsC donde R3 es hidrógeno o alquilo (C1-6), y donde cualquier grupo CH2 o CH3 dentro del grupo Q1-Z- opcionalmente lleva en cada uno de los dichos grupos CH2 o CH3 uno o más sustituyentes halógeno o alquilo (C1-6) o un sustituyente seleccionado entre hidroxi, ciano, amino, carboxi, carbamoilo, alcoxi (C1-6), alquiltio (C1-6), alquilsulfinilo (C1-6), alquilsulfonilo (C1-6), alquilamino (C1-6), di-[alquil (C1-6)]amino, alcoxicarbonilo (C1-6), N-alquilcarbamoilo (C1-6), N,N-di-[alquil (C1-6)]carbamoilo, alcanoilo (C2-6), alcanoiloxi (C2-6), alcanoilamino (C2-6), N-alquil (C1-6)-alcanoilamino (C2-6), N-alquilsulfamoilo (C1-6), N,N-di-[alquil (C1-6)]sulfamoilo, alcansulfonilamino (C1-6) y N-alquil (C1-6)-alcansulfonilamino (C1-6), y donde cualquier grupo heterociclilo, cicloalquilo (C3-7) o cicloalquelino (C3-7) dentro del grupo Q1-Z- opcionalmente lleva 1, 2 ó 3 sustituyentes, que pueden ser iguales o diferentes, seleccionados entre halógeno, trifluorometilo, ciano, nitro, hidroxi, amino, carboxi, carbamoilo, formilo, alquilo (C1-6), alquenilo (C2-8), alquinilo (C2-8), alcoxi (C1-6), alqueniloxi (C2-6), alquiniloxi (C2-6), alquiltio (C1-6), alquilsulfinilo (C1-6), alquilsulfonilo (C1-6), alquilamino (C1-6), di-[alquil (C1-6)]amino, alcoxicarbonilo (C1-6), N-alquilcarbamoilo (C1-6), N,N-di-[alquil (C1-6)]carbamoilo, alcanoilo (C2-6), alcanoiloxi (C2-6), amino-alcanoilo (C2-6), N-alquilamino (C1-6)-alcanoilo (C2-6), N,N-di-[alquil (C1-6)]amino-alcanoilo (C2-6), alcanoilamino (C2-6), N-alquil (C1-6)-alcanoilamino (C2-6), N-alquilsulfamoilo (C1-6), N,N-di-[alquil (C1-6)]sulfamoilo, alcansulfonilamino (C1-6), N-alquil (C1-6)-alcansulfonilamino (C1-6), de un grupo de la fórmula: -X1-R4, donde X1 es un enlace, directo o se selecciona entre O y N(R5), donde R5 es hidrógeno o alquilo (C1-6), y R4 es halógeno-alquilo (C1-6), hidroxi-alquilo (C1-6), alcoxi (C1-6)-alquilo (C1-6), ciano-alquilo (C1-6), carboxi-alquilo (C1-6), amino-alquilo (C1-6), alquilamino (C1-6)-alquilo (C1-6), di-[alquil (C1-6)]amino-alquilo (C1-6), carbamoil-alquilo (C1-6), N-alquilcarbonil (C1-6)-alquilo (C1-6), N,N-di-[alquil (C1-6)]carbamoil-alquilo (C1-6), alcanoil (C2-6)-alquilo (C1-6) o alcoxicarbonil (C1-6)-alquilo (C1-6), y un grupo de la fórmula: -X5-Q6 donde X5 es un enlace directo o se selecciona entre O, CO, y N(R10), donde R10 es hidrógeno o alquilo (C1-6), y Q6 es heterociclilo, heterociclil-alquilo (C1-6), cicloalquilo (C3-7), cicloalquil (C3-7)-alquilo (C1-6), cicloalquenilo (C3-7) o cicloalquenil (C3-7)-alquilo (C1-6), y en donde cualquier grupo heterociclilo, cicloalquilo (C3-7) o cicloalquenilo (C3-7) en Q6 opcionalmente lleva 1 ó 2 sustituyentes, que pueden ser iguales o diferentes, seleccionados entre halógeno, hidroxi, ciano, formilo, alquilo (C1-6), alquenilo (C2-6), alquinilo (C2-6), alcoxi (C1-6), amino, alquilamino (C1-6), di[alquil (C1-6)]amino, alcanoilo (C2-6), alcoxicarbonilo (C1-6), alquilsulfinilo (C1-6), carbamoilo, N-(C1-6)alquilcarbamoilo, N,N-di-[alquil (C1-6)]carbamoilo, halógeno-alquilo (C1-6), hidroxi-alquilo (C1-6), alcoxi (C1-6)-alquilo (C1-6), ciano-alquilo (C1-6), carboxi-alquilo (C1-6), amino-alquilo (C1-6), alquilamino (C1-6)-alquilo (C1-6), di-[alquil (C1-6)]amino-alquilo (C1-6), carbamoil-alquilo (C1-6), N-alquilcarbamoil (C1-6)-alquilo (C1-6) y N,N-di-[alquil (C1-6)]carbamoil-alquilo (C1-6), y donde cualquier grupo heterociclilo dentro del grupo Q1-Z- opcionalmente lleva 1 ó 2 sustituyentes oxo o tioxo; y Q2 se selecciona entre el grupo de fórmulas (2), donde G1, G2, G3, G4 y G5 son cada uno, independientemente, seleccionado entre hidrógeno, halógeno, trifluorometilo, ciano, nitro, hidroxi, amino, carboxi, carbamoilo, alquilo (C1-6), alquenilo (C2-8), alquinilo (C2-8), alcoxi (C1-6), alqueniloxi (C2-6), alquiniloxi (C2-6), alquilamino (C1-6) y di-[alquil (C1-6)]amino, G6 y G7 son cada uno, independientemente, seleccionado entre hidrógeno y halógeno, X2 es un enlace directo o se selecciona entre O, S, SO, SO2, N(R6), CH(OR6), CON(R6), N(R6)CO, SO2N(R6), N(R6)SO2, OC(R6)2, C(R6)2O, SC(R6)2, C(R6)2S, CO, C(R6)2N(R6) y N(R6)C(R6)2 donde cada R6 es, independientemente, hidrógeno o alquilo (C1-6), y Q3 es arilo, o heteroarilo, o X2 es CO y Q3 es un grupo heterociclilo con contenido de nitrógeno unido a X2 por un átomo de nitrógeno, X3 es un enlace directo o se selecciona entre SO2, CO, SO2N(R) y C(R7)2, donde cada R7 es, independientemente, hidrógeno o alquilo (C1-6), y Q4 es arilo o heteroarilo, y cualquier grupo arilo, heteroarilo o heterociclilo en el grupo -X2-Q3 y -X3-Q4 opcionalmente lleva 1, 2 ó 3 sustituyentes, que pueden ser iguales o diferentes, seleccionados entre halógeno, trifluorometilo, ciano, nitro, hidroxi, amino, carboxi, formilo, carbamoilo, sulfamoilo, mercapto, alquilo (C1-6), alquenilo (C2-8), alquinilo (C2-8), alcoxi (C1-6), alqueniloxi (C2-6), alquiniloxi (C2-6), alquiltio (C1-6), alquilsulfinilo (C1-6), alquilsulfonilo (C1-6), alquilamino (C1-6), di-[alquil (C1-6)]amino, alcoxicarbonilo (C1-6), N-alquilcarbamoilo (C1-6), N,N-di-[alquil(C1-6)]carbamoilo, alcanoilo (C2-6), alcanoiloxi (C2-6), alcanoilamino (C2-6), N-alquil (C1-6)-alcanoilamino (C2-6), N-alquilsulfamoilo (C1-6), N,N-di-[alquil(C1-6)]sulfamoilo, alcansulfonilamino (C1-6) y N-alquil (C1-6)-alcansulfonilamino (C1-6), o es un grupo de la fórmula X4-R8 donde X4 es un enlace directo o se selecciona entre O y N(R9), donde R9 es hidrógeno o alquilo (C1-6), y R8 es halógeno-alquilo (C1-6), hidroxi-alquilo (C1-6), alcoxi-alquilo (C1-6), ciano-alquilo (C1-6), carboxi-alquilo (C1-6), amino-alquilo (C1-6), alquilamino (C1-6)-alquilo (C1-6), di-[alquil (C1-6)]amino-alquilo (C1-6), carbamoilo-alquilo (C1-6), N-alquilcarbamoil (C1-6)-alquilo (C1-6), N,N-di-[alquil (C1-6)]carbamoil-alquilo (C1-6), alcanoil (C2-6)-alquilo (C1-6) o alcoxicarbonil (C1-6)-alquilo (C1-6), o es un grupo de la fórmula -Q5 donde Q5 se selecciona entre arilo, heteroarilo o heterociclilo que es opcionalmente sustituido por 1 ó 2 sustituyentes seleccionados entre halógeno, hidroxi, alquilo (C1-6), alcoxi (C1-6), amino, alquilamino (C1-6) y di-[alquil(C1-6)]amino, y donde cualquier grupo CH2 o CH3 dentro de un sustituyente en cualquier grupo arilo, heteroarilo o heterociclilo en el grupo -X2-Q3 y -X3-Q4 opcionalmente lleva en cada uno de dichos grupos CH2 o CH3 uno o más sustituyentes halógeno o alquilo (C1-6), y cualquier grupo heterociclilo representado por Q3 o Q4 opcionalmente lleva 1 ó 2 sustituyentes oxo o tioxo, o una sal aceptable para uso farmacéutico del mismo. Los procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en la fabricación de un medicamento para usar en la prevención o tratamiento de tumores que son sensibles a la inhibición de miembros de la familia erbB de tirosina quinasas de receptor, también se describen.
ARP020104181A 2001-11-03 2002-11-01 Derivado de quinazolina, composicion farmaceutica, su uso en la fabricacion de un medicamento y proceso para preparar dicho derivado de quinazolina AR037330A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0126433.2A GB0126433D0 (en) 2001-11-03 2001-11-03 Compounds
GB0129059A GB0129059D0 (en) 2001-12-05 2001-12-05 Compounds

Publications (1)

Publication Number Publication Date
AR037330A1 true AR037330A1 (es) 2004-11-03

Family

ID=26246737

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020104181A AR037330A1 (es) 2001-11-03 2002-11-01 Derivado de quinazolina, composicion farmaceutica, su uso en la fabricacion de un medicamento y proceso para preparar dicho derivado de quinazolina

Country Status (22)

Country Link
US (2) US20050043336A1 (es)
EP (1) EP1444210B1 (es)
JP (1) JP2005515176A (es)
KR (1) KR20050042055A (es)
CN (1) CN100343238C (es)
AR (1) AR037330A1 (es)
AT (1) ATE423104T1 (es)
BR (1) BR0213842A (es)
CA (1) CA2465068A1 (es)
CO (1) CO5580774A2 (es)
DE (1) DE60231230D1 (es)
ES (1) ES2320980T3 (es)
HU (1) HUP0401646A2 (es)
IL (1) IL161619A0 (es)
IS (1) IS7240A (es)
MX (1) MXPA04004219A (es)
NO (1) NO20042279L (es)
NZ (1) NZ532524A (es)
PL (1) PL369938A1 (es)
RU (1) RU2004116911A (es)
TW (1) TW200301702A (es)
WO (1) WO2003040108A1 (es)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002076976A2 (en) * 2001-03-23 2002-10-03 Bayer Corporation Rho-kinase inhibitors
CA2441501C (en) * 2001-03-23 2010-09-14 Bayer Corporation Rho-kinase inhibitors
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
RU2362775C1 (ru) * 2002-02-01 2009-07-27 Астразенека Аб Хиназолиновые соединения
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US7488823B2 (en) * 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
AU2003292435A1 (en) * 2002-12-23 2004-07-14 Astrazeneca Ab 4- (pyridin-4-ylamino) -quinazoline derivatives as anti-tumor agents
TW200503994A (en) * 2003-01-24 2005-02-01 Novartis Ag Organic compounds
GB0309009D0 (en) * 2003-04-22 2003-05-28 Astrazeneca Ab Quinazoline derivatives
GB0309850D0 (en) * 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
EP1636195A1 (en) * 2003-05-27 2006-03-22 Pfizer Products Inc. Quinazolines and pyrido[3,4-d]pyrimidines as receptor tyrosine kinase inhibitors
AU2004256124B2 (en) * 2003-07-02 2011-04-28 Corus Pharma, Inc. Aztreonam L-lysine and methods for the preparation thereof
KR101218213B1 (ko) 2003-07-03 2013-01-04 시토비아 인크. 카스파제의 활성인자 및 세포자멸사의 유도인자로서의4-아릴아미노-퀴나졸린
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
GB0317665D0 (en) 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
NZ545459A (en) * 2003-08-14 2009-12-24 Array Biopharma Inc Quinazoline analogs as receptor tyrosine kinase inhibitors
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
AU2004272345A1 (en) * 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives
GB0321648D0 (en) * 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
JP2007505871A (ja) * 2003-09-16 2007-03-15 アストラゼネカ アクチボラグ キナゾリン誘導体
JP2007505873A (ja) * 2003-09-16 2007-03-15 アストラゼネカ アクチボラグ チロシンキナーゼ阻害剤としてのキナゾリン誘導体
ATE395346T1 (de) * 2003-09-16 2008-05-15 Astrazeneca Ab Chinazolinderivate als tyrosinkinaseinhibitoren
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
US20050267182A1 (en) * 2003-11-13 2005-12-01 Ambit Biosciences Corporation Urea derivatives as FLT-3 modulators
GB0326459D0 (en) * 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
CN110522717A (zh) 2004-01-22 2019-12-03 迈阿密大学 局部辅酶q10制剂及其使用方法
EP1713484A2 (en) 2004-01-23 2006-10-25 Amgen Inc. Compounds and methods of use
WO2005073224A2 (en) 2004-01-23 2005-08-11 Amgen Inc Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer
ES2315834T3 (es) * 2004-02-03 2009-04-01 Astrazeneca Ab Derivados de quinazolina.
FR2866887A1 (fr) * 2004-02-27 2005-09-02 Oreal Para-phenylenediamine secondaire n-heteroaryle, compositon tinctoriale comprenant une telle para-phenylenediamine, procede mettant en oeuvre cette composition et utilisation
WO2005107758A1 (en) 2004-05-06 2005-11-17 Warner-Lambert Company Llc 4-phenylamino-quinazolin-6-yl-amides
JP2008501675A (ja) * 2004-06-04 2008-01-24 アストラゼネカ アクチボラグ Ｅｒｂｂ受容体型チロシンキナーゼとしてのキナゾリン誘導体
JP2008513463A (ja) 2004-09-15 2008-05-01 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ チアゾロピリジンキナーゼ阻害剤
KR20070084172A (ko) 2004-10-12 2007-08-24 아스트라제네카 아베 퀴나졸린 유도체
EP1827434B1 (en) 2004-11-30 2014-01-15 Amgen Inc. Quinolines and quinazoline analogs and their use as medicaments for treating cancer
ES2310861T3 (es) * 2004-12-08 2009-01-16 Bristol-Myers Squibb Company Compuestos heterociclicos como inhibidores del factor viia.
JP4881875B2 (ja) * 2004-12-14 2012-02-22 アストラゼネカ アクチボラグ 抗腫瘍剤としてのピラゾロピリミジン化合物
EP1833482A4 (en) 2005-01-03 2011-02-16 Myriad Genetics Inc COMPOUNDS AND ITS THERAPEUTIC USE
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
WO2006081741A1 (en) * 2005-02-05 2006-08-10 Piaoyang Sun Quinazoline compounds or their medical salts and preparation and medical usage thereof
GB0504475D0 (en) * 2005-03-04 2005-04-13 Astrazeneca Ab Chemical compounds
GB0504474D0 (en) * 2005-03-04 2005-04-13 Astrazeneca Ab Chemical compounds
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
GB0508715D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
GB0508717D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
WO2006118749A1 (en) * 2005-05-04 2006-11-09 Janssen Pharmaceutica, N.V. Thia-tetraazaacenaphthylene kinase inhibitors
DE602006018331D1 (de) 2005-09-20 2010-12-30 Astrazeneca Ab 4-(1h-indazol-5-ylamino)chinazolinverbindungen als inhibitoren der erbb-rezeptortyrosinkinase zur behandlung von krebs
WO2007034143A1 (en) * 2005-09-20 2007-03-29 Astrazeneca Ab Quinazoline derivatives as anticancer agents
CN102887891B (zh) 2005-11-15 2016-03-09 阿雷生物药品公司 N4-苯基-喹唑啉-4-胺衍生物和相关化合物
WO2007063291A1 (en) 2005-12-02 2007-06-07 Astrazeneca Ab 4-anilino-substituted quinazoline derivatives as tyrosine kinase inhibitors
ATE443053T1 (de) * 2005-12-02 2009-10-15 Astrazeneca Ab Als inhibitoren von erbb-tyrosinkinase verwendete chinazoleinderivate
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
JP2009544609A (ja) * 2006-07-18 2009-12-17 アストラゼネカ・アクチエボラーグ 置換２−アセチルアミノ−アルコキシフェニルの製造方法
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
FR2912145B1 (fr) * 2007-02-02 2009-03-06 Servier Lab Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
BRPI0807234A2 (pt) 2007-02-06 2014-06-03 Boehringer Ingelheim Int Heterociclos bicíclicos, composições farmacêuticas que contêm estes compostos, o uso dos mesmos e processos para a preparação dos mesmos
AU2008236670B2 (en) * 2007-04-05 2011-12-01 Amgen Inc. Aurora kinase modulators and method of use
US7795254B2 (en) * 2007-10-29 2010-09-14 Amgen Inc. Benzomorpholine derivatives and methods of use
EP2220054A2 (en) 2007-10-29 2010-08-25 Natco Pharma Limited Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents
KR20100111291A (ko) 2008-02-07 2010-10-14 베링거 인겔하임 인터내셔날 게엠베하 스피로사이클릭 헤테로사이클, 상기 화합물을 함유하는 약제, 이의 용도 및 이의 제조 방법
EP3015104A1 (en) 2008-04-11 2016-05-04 Berg LLC Methods and use of inducing apoptosis in cancer cells
MY183041A (en) 2008-05-13 2021-02-08 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- {[1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy}quinazoline
CA2733153C (en) 2008-08-08 2016-11-08 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
SG10201402287TA (en) 2009-05-11 2014-07-30 Berg Llc Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
KR101933732B1 (ko) 2011-04-04 2018-12-28 버그 엘엘씨 중추 신경 시스템 종양들의 치료 방법
WO2014168993A1 (en) 2013-04-08 2014-10-16 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
ES2825083T3 (es) 2013-09-04 2021-05-14 Berg Llc Métodos de tratamiento contra el cáncer mediante infusión continua de coenzima Q10
CN105916506B (zh) 2013-11-20 2020-01-07 圣诺康生命科学公司 作为tam家族激酶抑制剂的喹唑啉衍生物
WO2016021742A1 (en) 2014-08-07 2016-02-11 Takeda Pharmaceutical Company Limited Heterocyclic compounds as ep4 receptor antagonists
WO2017087576A1 (en) 2015-11-16 2017-05-26 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
CN106831599B (zh) * 2017-03-03 2019-08-23 南京理工大学 一种合成1-二氟甲基咪唑及其衍生物的方法
CN107400094B (zh) * 2017-09-08 2020-04-03 贾玉庆 喹唑啉基羧酸酯类化合物及其用途
CN108285421A (zh) * 2018-01-26 2018-07-17 黑龙江鑫创生物科技开发有限公司 一种微通道反应器合成拉帕替尼中间体的方法
AR117424A1 (es) * 2018-05-08 2021-08-04 Dizal Jiangsu Pharmaceutical Co Ltd Inhibidores de los receptores erbb
JP7546550B2 (ja) * 2018-09-18 2024-09-06 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗腫瘍剤としてのキナゾリン誘導体
CN109336828B (zh) * 2018-11-30 2022-04-26 雅安职业技术学院 一种喹唑啉衍生物及其制备方法和应用
CN113200945A (zh) * 2021-04-23 2021-08-03 上海应用技术大学 一种芳香胺化合物的制备方法
CN115894383B (zh) * 2021-09-30 2025-12-19 北京赛特明强医药科技有限公司 一种喹唑啉类化合物、组合物及其应用
TW202446386A (zh) * 2023-04-14 2024-12-01 大陸商迪哲（江蘇）醫藥股份有限公司 喹唑啉ＥｒｂＢ抑制劑的藥物形式

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5538325A (en) * 1978-09-11 1980-03-17 Sankyo Co Ltd 4-anilinoquinazoline derivative and its preparation
GB2160201B (en) * 1984-06-14 1988-05-11 Wyeth John & Brother Ltd Quinazoline and cinnoline derivatives
CA1340821C (en) * 1988-10-06 1999-11-16 Nobuyuki Fukazawa Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (es) * 1994-11-12 1997-12-01 Zeneca Ltd
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
GB9514265D0 (en) * 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
AU1721697A (en) * 1996-01-31 1997-08-22 Gist-Brocades B.V. Use of compositions comprising stabilized biologically effective compounds
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
EP0912559B1 (en) * 1996-07-13 2002-11-06 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
US6004967A (en) * 1996-09-13 1999-12-21 Sugen, Inc. Psoriasis treatment with quinazoline compounds
AR012634A1 (es) * 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US5929080A (en) * 1997-05-06 1999-07-27 American Cyanamid Company Method of treating polycystic kidney disease
US6384223B1 (en) * 1998-07-30 2002-05-07 American Home Products Corporation Substituted quinazoline derivatives
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
UA73993C2 (uk) * 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
WO2003031406A2 (en) * 2001-10-12 2003-04-17 Irm Llc Kinase inhibitor scaffolds and methods for their preparation
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
TWI324597B (en) * 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
US6924285B2 (en) * 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
GB0309009D0 (en) * 2003-04-22 2003-05-28 Astrazeneca Ab Quinazoline derivatives
GB0309850D0 (en) * 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
GB0317665D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
WO2005012290A1 (en) * 2003-07-29 2005-02-10 Astrazeneca Ab Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
GB0321648D0 (en) * 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
JP2007505871A (ja) * 2003-09-16 2007-03-15 アストラゼネカ アクチボラグ キナゾリン誘導体
ATE395346T1 (de) * 2003-09-16 2008-05-15 Astrazeneca Ab Chinazolinderivate als tyrosinkinaseinhibitoren
JP2007505873A (ja) * 2003-09-16 2007-03-15 アストラゼネカ アクチボラグ チロシンキナーゼ阻害剤としてのキナゾリン誘導体
EP1670782B1 (en) * 2003-09-19 2007-02-14 AstraZeneca AB Quinazoline derivatives
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
CA2540008A1 (en) * 2003-09-25 2005-04-07 Astrazeneca Ab Quinazoline derivatives
GB0326459D0 (en) * 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
ES2315834T3 (es) * 2004-02-03 2009-04-01 Astrazeneca Ab Derivados de quinazolina.
JP2008501675A (ja) * 2004-06-04 2008-01-24 アストラゼネカ アクチボラグ Ｅｒｂｂ受容体型チロシンキナーゼとしてのキナゾリン誘導体

Also Published As

Publication number Publication date
US20070082921A1 (en) 2007-04-12
IL161619A0 (en) 2004-09-27
JP2005515176A (ja) 2005-05-26
EP1444210A1 (en) 2004-08-11
IS7240A (is) 2004-04-30
HUP0401646A2 (hu) 2004-12-28
RU2004116911A (ru) 2005-11-10
DE60231230D1 (de) 2009-04-02
ES2320980T3 (es) 2009-06-01
CN100343238C (zh) 2007-10-17
HK1066218A1 (en) 2005-03-18
EP1444210B1 (en) 2009-02-18
ATE423104T1 (de) 2009-03-15
BR0213842A (pt) 2004-08-31
CA2465068A1 (en) 2003-05-15
CN1585754A (zh) 2005-02-23
PL369938A1 (en) 2005-05-02
KR20050042055A (ko) 2005-05-04
NZ532524A (en) 2007-02-23
US20050043336A1 (en) 2005-02-24
WO2003040108A1 (en) 2003-05-15
NO20042279L (no) 2004-06-02
MXPA04004219A (es) 2004-09-10
CO5580774A2 (es) 2005-11-30
TW200301702A (en) 2003-07-16

Similar Documents

Publication Publication Date Title
AR037330A1 (es) Derivado de quinazolina, composicion farmaceutica, su uso en la fabricacion de un medicamento y proceso para preparar dicho derivado de quinazolina
AR037193A1 (es) Derivados de quinazolina, composicion farmaceutica, su uso en la fabricacion de un medicamento y procesopara preparar dicho derivado de quinazolina
AR033560A1 (es) Derivados de quinazolina, proceso para su preparacion, composicion farmaceutica, y su uso en la fabricacion de un medicamento,
AR045663A1 (es) Derivados de quinazolina
RU2434017C2 (ru) Миметики с обратной конфигурацией и относящиеся к ним способы
PE20030062A1 (es) Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas
NO20025641D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
EA200500018A1 (ru) Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения
AR069078A1 (es) Derivados de piridina y pirazina
ES2128092T3 (es) Derivados de anilina.
EA200600892A1 (ru) Новые хинолиновые производные
AR046308A1 (es) Derivados amida
PT1263730E (pt) Derivados amina para o tratamento de apoptose
SE0300119D0 (sv) Novel compounds
NO20025640D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
AR046452A1 (es) Derivados de quinazolina, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso como medicamento con efecto antiproliferativo
PE20090712A1 (es) Moduladores de la gamma secretasa
ATE368666T1 (de) Pyrazolopyrimidinone und ihre verwendung als pde inhibitoren
MY133445A (en) 2-arylethyl-(piperidin-4-ylmethyl)amine derivetives
PE20081703A1 (es) Nuevos derivados triciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
SE0102055D0 (sv) New Compounds
IL159880A0 (en) Arylsulfonyl derivatives with 5-ht6 receptor affinity
TW200504014A (en) Indol-5-yl sulfonamide derivatives, their preparation and their use in medicaments
AU2003250701A1 (en) Protein tyrosine kinase inhibitors

Legal Events

Date Code Title Description
FA Abandonment or withdrawal